ZA200307121B - Cell-based detection and differentiation of disease states. - Google Patents
Cell-based detection and differentiation of disease states. Download PDFInfo
- Publication number
- ZA200307121B ZA200307121B ZA200307121A ZA200307121A ZA200307121B ZA 200307121 B ZA200307121 B ZA 200307121B ZA 200307121 A ZA200307121 A ZA 200307121A ZA 200307121 A ZA200307121 A ZA 200307121A ZA 200307121 B ZA200307121 B ZA 200307121B
- Authority
- ZA
- South Africa
- Prior art keywords
- panel
- probes
- probe
- marker
- lung cancer
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 306
- 201000010099 disease Diseases 0.000 title claims description 303
- 238000001514 detection method Methods 0.000 title claims description 144
- 230000004069 differentiation Effects 0.000 title claims description 21
- 239000000523 sample Substances 0.000 claims description 638
- 210000004027 cell Anatomy 0.000 claims description 268
- 238000000034 method Methods 0.000 claims description 250
- 206010028980 Neoplasm Diseases 0.000 claims description 233
- 239000003550 marker Substances 0.000 claims description 188
- 208000020816 lung neoplasm Diseases 0.000 claims description 163
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 145
- 201000005202 lung cancer Diseases 0.000 claims description 144
- 201000011510 cancer Diseases 0.000 claims description 125
- 238000004458 analytical method Methods 0.000 claims description 110
- 230000035945 sensitivity Effects 0.000 claims description 78
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 208000009956 adenocarcinoma Diseases 0.000 claims description 59
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 55
- 210000001519 tissue Anatomy 0.000 claims description 55
- 206010027406 Mesothelioma Diseases 0.000 claims description 51
- 239000000427 antigen Substances 0.000 claims description 51
- 102000036639 antigens Human genes 0.000 claims description 51
- 108091007433 antigens Proteins 0.000 claims description 51
- 102000004169 proteins and genes Human genes 0.000 claims description 50
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 49
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 49
- 230000027455 binding Effects 0.000 claims description 48
- 208000003849 large cell carcinoma Diseases 0.000 claims description 47
- 206010036790 Productive cough Diseases 0.000 claims description 45
- 239000011159 matrix material Substances 0.000 claims description 45
- 210000003802 sputum Anatomy 0.000 claims description 45
- 208000024794 sputum Diseases 0.000 claims description 45
- 108050006400 Cyclin Proteins 0.000 claims description 44
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims description 41
- 238000003745 diagnosis Methods 0.000 claims description 40
- 102000000905 Cadherin Human genes 0.000 claims description 34
- 108050007957 Cadherin Proteins 0.000 claims description 34
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 33
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 32
- 230000008569 process Effects 0.000 claims description 31
- 208000000649 small cell carcinoma Diseases 0.000 claims description 29
- 102000001301 EGF receptor Human genes 0.000 claims description 26
- 108060006698 EGF receptor Proteins 0.000 claims description 26
- 102100026966 Thrombomodulin Human genes 0.000 claims description 26
- 108010079274 Thrombomodulin Proteins 0.000 claims description 26
- 210000004072 lung Anatomy 0.000 claims description 24
- 108010068192 Cyclin A Proteins 0.000 claims description 21
- 108010058546 Cyclin D1 Proteins 0.000 claims description 21
- 102100025191 Cyclin-A2 Human genes 0.000 claims description 21
- 230000003902 lesion Effects 0.000 claims description 20
- 230000002380 cytological effect Effects 0.000 claims description 18
- -1 nm23 Proteins 0.000 claims description 18
- 238000004163 cytometry Methods 0.000 claims description 17
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 16
- 239000000090 biomarker Substances 0.000 claims description 16
- 108010008707 Mucin-1 Proteins 0.000 claims description 15
- 108010017842 Telomerase Proteins 0.000 claims description 15
- 230000001413 cellular effect Effects 0.000 claims description 15
- 201000009030 Carcinoma Diseases 0.000 claims description 14
- 210000002919 epithelial cell Anatomy 0.000 claims description 13
- 238000007901 in situ hybridization Methods 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000002159 abnormal effect Effects 0.000 claims description 11
- 230000022131 cell cycle Effects 0.000 claims description 11
- 230000002685 pulmonary effect Effects 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 11
- 238000001574 biopsy Methods 0.000 claims description 9
- 238000012737 microarray-based gene expression Methods 0.000 claims description 9
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 8
- 108050000637 N-cadherin Proteins 0.000 claims description 8
- 230000002068 genetic effect Effects 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 210000001685 thyroid gland Anatomy 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000000877 morphologic effect Effects 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 108010057966 Thyroid Nuclear Factor 1 Proteins 0.000 claims description 6
- 102000002658 Thyroid Nuclear Factor 1 Human genes 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 238000013528 artificial neural network Methods 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 238000003364 immunohistochemistry Methods 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 238000012567 pattern recognition method Methods 0.000 claims description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 102000043276 Oncogene Human genes 0.000 claims description 4
- 108700020796 Oncogene Proteins 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 4
- 238000003365 immunocytochemistry Methods 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 210000004789 organ system Anatomy 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 210000005000 reproductive tract Anatomy 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 206010018612 Gonorrhoea Diseases 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 208000001786 gonorrhea Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 208000006379 syphilis Diseases 0.000 claims description 3
- 210000001635 urinary tract Anatomy 0.000 claims description 3
- 241000606161 Chlamydia Species 0.000 claims description 2
- 108020005124 DNA Adducts Proteins 0.000 claims description 2
- 230000009946 DNA mutation Effects 0.000 claims description 2
- 241000224526 Trichomonas Species 0.000 claims description 2
- 230000001640 apoptogenic effect Effects 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 102100021599 GTPase Era, mitochondrial Human genes 0.000 claims 10
- 101100065513 Homo sapiens ERAL1 gene Proteins 0.000 claims 10
- 102100034256 Mucin-1 Human genes 0.000 claims 5
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 claims 4
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 claims 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 4
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 claims 2
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 claims 2
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 claims 2
- 230000005670 electromagnetic radiation Effects 0.000 claims 2
- 238000000386 microscopy Methods 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 claims 1
- 101150021185 FGF gene Proteins 0.000 claims 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 130
- 230000014509 gene expression Effects 0.000 description 107
- 230000006870 function Effects 0.000 description 54
- 239000004094 surface-active agent Substances 0.000 description 49
- 108010083590 Apoproteins Proteins 0.000 description 45
- 102000006410 Apoproteins Human genes 0.000 description 45
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 38
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 37
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 36
- 230000001028 anti-proliverative effect Effects 0.000 description 33
- 238000003066 decision tree Methods 0.000 description 33
- 230000002962 histologic effect Effects 0.000 description 33
- 208000000587 small cell lung carcinoma Diseases 0.000 description 31
- 102000019040 Nuclear Antigens Human genes 0.000 description 29
- 108010051791 Nuclear Antigens Proteins 0.000 description 29
- 238000010186 staining Methods 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 28
- 238000002790 cross-validation Methods 0.000 description 28
- 238000013461 design Methods 0.000 description 27
- 230000004083 survival effect Effects 0.000 description 26
- 241000282414 Homo sapiens Species 0.000 description 25
- 230000002018 overexpression Effects 0.000 description 24
- 230000030570 cellular localization Effects 0.000 description 23
- 238000007477 logistic regression Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 102000006311 Cyclin D1 Human genes 0.000 description 20
- 230000003211 malignant effect Effects 0.000 description 20
- 238000013459 approach Methods 0.000 description 19
- 238000005516 engineering process Methods 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 19
- 238000013138 pruning Methods 0.000 description 19
- 238000007619 statistical method Methods 0.000 description 19
- 238000004422 calculation algorithm Methods 0.000 description 18
- 239000003580 lung surfactant Substances 0.000 description 18
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 18
- 238000012549 training Methods 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- 206010041067 Small cell lung cancer Diseases 0.000 description 15
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 14
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 14
- 238000002591 computed tomography Methods 0.000 description 14
- 229940126864 fibroblast growth factor Drugs 0.000 description 14
- 230000004807 localization Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 238000000540 analysis of variance Methods 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 238000002405 diagnostic procedure Methods 0.000 description 13
- 206010061289 metastatic neoplasm Diseases 0.000 description 13
- 230000007170 pathology Effects 0.000 description 13
- 238000012552 review Methods 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 12
- 238000005192 partition Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 230000001976 improved effect Effects 0.000 description 11
- 108091007914 CDKs Proteins 0.000 description 10
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 10
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 10
- 206010027476 Metastases Diseases 0.000 description 10
- 102000007298 Mucin-1 Human genes 0.000 description 10
- 206010061309 Neoplasm progression Diseases 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 230000002559 cytogenic effect Effects 0.000 description 10
- 230000001086 cytosolic effect Effects 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 10
- 230000009401 metastasis Effects 0.000 description 10
- 239000003147 molecular marker Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000005751 tumor progression Effects 0.000 description 10
- 102100032912 CD44 antigen Human genes 0.000 description 9
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 102000015694 estrogen receptors Human genes 0.000 description 9
- 108010038795 estrogen receptors Proteins 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 8
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 8
- 102100037901 Pre-mRNA-splicing factor SYF2 Human genes 0.000 description 8
- 230000003127 anti-melanomic effect Effects 0.000 description 8
- 238000007405 data analysis Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000036210 malignancy Effects 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 7
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 238000010801 machine learning Methods 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 238000003909 pattern recognition Methods 0.000 description 7
- 238000004393 prognosis Methods 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000013077 scoring method Methods 0.000 description 7
- 206010008342 Cervix carcinoma Diseases 0.000 description 6
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 6
- 101710204288 Melanoma-associated antigen 3 Proteins 0.000 description 6
- 102000007999 Nuclear Proteins Human genes 0.000 description 6
- 108010089610 Nuclear Proteins Proteins 0.000 description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 238000013276 bronchoscopy Methods 0.000 description 6
- 201000010881 cervical cancer Diseases 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000009595 pap smear Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 208000009458 Carcinoma in Situ Diseases 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 108091052347 Glucose transporter family Proteins 0.000 description 5
- 102000042092 Glucose transporter family Human genes 0.000 description 5
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 5
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 5
- 230000018199 S phase Effects 0.000 description 5
- 101710100179 UMP-CMP kinase Proteins 0.000 description 5
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 201000004933 in situ carcinoma Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000001613 neoplastic effect Effects 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 238000010837 poor prognosis Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 4
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010058314 Dysplasia Diseases 0.000 description 4
- 206010014561 Emphysema Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102000015728 Mucins Human genes 0.000 description 4
- 108010063954 Mucins Proteins 0.000 description 4
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 4
- 108091058545 Secretory proteins Proteins 0.000 description 4
- 102000040739 Secretory proteins Human genes 0.000 description 4
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- 238000013523 data management Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000012827 research and development Methods 0.000 description 4
- 238000010187 selection method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102000016736 Cyclin Human genes 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 206010018691 Granuloma Diseases 0.000 description 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 3
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 206010054949 Metaplasia Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 102000052575 Proto-Oncogene Human genes 0.000 description 3
- 108700020978 Proto-Oncogene Proteins 0.000 description 3
- 108050002653 Retinoblastoma protein Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 231100000357 carcinogen Toxicity 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000011976 chest X-ray Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 238000002991 immunohistochemical analysis Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000015689 metaplastic ossification Effects 0.000 description 3
- 210000001700 mitochondrial membrane Anatomy 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 208000017572 squamous cell neoplasm Diseases 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 108091035539 telomere Proteins 0.000 description 3
- 102000055501 telomere Human genes 0.000 description 3
- 210000003411 telomere Anatomy 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000009452 underexpressoin Effects 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102000007528 DNA Polymerase III Human genes 0.000 description 2
- 108010071146 DNA Polymerase III Proteins 0.000 description 2
- 101100393884 Drosophila melanogaster Glut1 gene Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 230000010337 G2 phase Effects 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000009331 Homeodomain Proteins Human genes 0.000 description 2
- 108010048671 Homeodomain Proteins Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 description 2
- 108010070507 Keratin-7 Proteins 0.000 description 2
- 102000006835 Lamins Human genes 0.000 description 2
- 108010047294 Lamins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 108010088249 Monogen Proteins 0.000 description 2
- 108010008705 Mucin-2 Proteins 0.000 description 2
- 102100034263 Mucin-2 Human genes 0.000 description 2
- 108010008701 Mucin-3 Proteins 0.000 description 2
- 102000007295 Mucin-3 Human genes 0.000 description 2
- 102100022693 Mucin-4 Human genes 0.000 description 2
- 108010008699 Mucin-4 Proteins 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 101800001156 Protein p29 Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000012952 Resampling Methods 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108091006296 SLC2A1 Proteins 0.000 description 2
- 101150058068 SLC2A1 gene Proteins 0.000 description 2
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 102100029477 Vitamin K-dependent protein C Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000002588 alveolar type II cell Anatomy 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 230000007321 biological mechanism Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- 210000005178 buccal mucosa Anatomy 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000013479 data entry Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000012850 discrimination method Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 235000015220 hamburgers Nutrition 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000024312 invasive carcinoma Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000005053 lamin Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 201000009546 lung large cell carcinoma Diseases 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000009607 mammography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 239000012120 mounting media Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 238000011369 optimal treatment Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000013102 re-test Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101001130128 Arabidopsis thaliana Leucoanthocyanidin dioxygenase Proteins 0.000 description 1
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000514744 Cyclina Species 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
- 101001112318 Dictyostelium discoideum Nucleoside diphosphate kinase, cytosolic Proteins 0.000 description 1
- 101001112320 Dictyostelium discoideum Nucleoside diphosphate kinase, mitochondrial Proteins 0.000 description 1
- 101100230254 Drosophila melanogaster Glut3 gene Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 241000611421 Elia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 101150019331 FGF2 gene Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 238000001159 Fisher's combined probability test Methods 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 108091008603 HGF receptors Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- 101710170207 High-affinity glucose transporter Proteins 0.000 description 1
- 101001128731 Homo sapiens Putative nucleoside diphosphate kinase Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000906283 Homo sapiens Solute carrier family 2, facilitated glucose transporter member 1 Proteins 0.000 description 1
- 101000785632 Homo sapiens Zinc finger FYVE domain-containing protein 21 Proteins 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
- 102100040487 Keratin, type I cytoskeletal 13 Human genes 0.000 description 1
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 1
- 102100040441 Keratin, type I cytoskeletal 16 Human genes 0.000 description 1
- 102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 description 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 description 1
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 1
- 108010065038 Keratin-10 Proteins 0.000 description 1
- 108010065070 Keratin-13 Proteins 0.000 description 1
- 108010066321 Keratin-14 Proteins 0.000 description 1
- 108010066364 Keratin-16 Proteins 0.000 description 1
- 108010066325 Keratin-17 Proteins 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 108010066370 Keratin-20 Proteins 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 206010023774 Large cell lung cancer Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 230000027311 M phase Effects 0.000 description 1
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 description 1
- 101710134306 Macrophage scavenger receptor types I and II Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 101710149892 Nucleoside diphosphate kinase B Proteins 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000275475 Praia Species 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 102100022407 Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase Human genes 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102100028588 Protein ZNRD2 Human genes 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 102100032116 Putative nucleoside diphosphate kinase Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101150052594 SLC2A3 gene Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- GRXKLBBBQUKJJZ-UHFFFAOYSA-N Soman Chemical compound CC(C)(C)C(C)OP(C)(F)=O GRXKLBBBQUKJJZ-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 206010053871 Trisomy 8 Diseases 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 101150030763 Vegfa gene Proteins 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 241001537287 Viscum minimum Species 0.000 description 1
- 101710193900 Vitamin K-dependent protein C Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102100026462 Zinc finger FYVE domain-containing protein 21 Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 101150000319 aer gene Proteins 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000003583 cytomorphological effect Effects 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000002375 environmental carcinogen Substances 0.000 description 1
- 239000003239 environmental mutagen Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003455 independent Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 101150024228 mdm2 gene Proteins 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000020474 morphogenesis of a polarized epithelium Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000299 nuclear matrix Anatomy 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 238000010831 paired-sample T-test Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 210000004043 pneumocyte Anatomy 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012066 statistical methodology Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 208000034298 trisomy chromosome 8 Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27463801P | 2001-03-12 | 2001-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200307121B true ZA200307121B (en) | 2004-12-13 |
Family
ID=23049031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200307121A ZA200307121B (en) | 2001-03-12 | 2003-09-11 | Cell-based detection and differentiation of disease states. |
Country Status (10)
Country | Link |
---|---|
US (4) | US20030199685A1 (fr) |
EP (1) | EP1373896A2 (fr) |
JP (1) | JP2004526154A (fr) |
KR (1) | KR20030094281A (fr) |
CN (1) | CN1554025A (fr) |
CA (1) | CA2440753A1 (fr) |
IL (1) | IL157872A0 (fr) |
NZ (1) | NZ528205A (fr) |
WO (1) | WO2002073204A2 (fr) |
ZA (1) | ZA200307121B (fr) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002529704A (ja) * | 1998-10-29 | 2002-09-10 | セル ワークス インコーポレイテッド | 単一細胞の複数マーカー特徴付け |
US20030190602A1 (en) * | 2001-03-12 | 2003-10-09 | Monogen, Inc. | Cell-based detection and differentiation of disease states |
US7043500B2 (en) * | 2001-04-25 | 2006-05-09 | Board Of Regents, The University Of Texas Syxtem | Subtractive clustering for use in analysis of data |
US7298877B1 (en) * | 2001-11-20 | 2007-11-20 | Icad, Inc. | Information fusion with Bayes networks in computer-aided detection systems |
CA2478850C (fr) * | 2002-03-13 | 2018-02-27 | Genomic Health, Inc. | Profilage d'expression genique dans des tissus tumoraux ponctionnes |
US7274809B2 (en) * | 2002-08-29 | 2007-09-25 | Perceptronix Medical, Inc. And British Columbia Cancer Agency | Computerized methods and systems related to the detection of malignancy-associated changes (MAC) to detect cancer |
EP2359689B1 (fr) | 2002-09-27 | 2015-08-26 | The General Hospital Corporation | Dispositif microfluidique pour la séparation de cellules et usage du dispositif |
EP1422526A1 (fr) * | 2002-10-28 | 2004-05-26 | MTM Laboratories AG | Procédé ameliorée de diagnostic des dysplasies |
US8008003B2 (en) * | 2002-11-15 | 2011-08-30 | Genomic Health, Inc. | Gene expression profiling of EGFR positive cancer |
US20040122708A1 (en) * | 2002-12-18 | 2004-06-24 | Avinash Gopal B. | Medical data analysis method and apparatus incorporating in vitro test data |
US20040122705A1 (en) * | 2002-12-18 | 2004-06-24 | Sabol John M. | Multilevel integrated medical knowledge base system and method |
US7490085B2 (en) * | 2002-12-18 | 2009-02-10 | Ge Medical Systems Global Technology Company, Llc | Computer-assisted data processing system and method incorporating automated learning |
US20040122707A1 (en) * | 2002-12-18 | 2004-06-24 | Sabol John M. | Patient-driven medical data processing system and method |
US20040122704A1 (en) * | 2002-12-18 | 2004-06-24 | Sabol John M. | Integrated medical knowledge base interface system and method |
US20040122787A1 (en) * | 2002-12-18 | 2004-06-24 | Avinash Gopal B. | Enhanced computer-assisted medical data processing system and method |
US20040122709A1 (en) * | 2002-12-18 | 2004-06-24 | Avinash Gopal B. | Medical procedure prioritization system and method utilizing integrated knowledge base |
US20040122706A1 (en) * | 2002-12-18 | 2004-06-24 | Walker Matthew J. | Patient data acquisition system and method |
US20040122702A1 (en) * | 2002-12-18 | 2004-06-24 | Sabol John M. | Medical data processing system and method |
US20040122703A1 (en) * | 2002-12-19 | 2004-06-24 | Walker Matthew J. | Medical data operating model development system and method |
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
CA2515096A1 (fr) * | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Marqueurs d'expression genique utilises en vue d'une reaction a des medicaments inhibiteurs de egfr |
EP1597391B1 (fr) * | 2003-02-20 | 2008-10-29 | Genomic Health, Inc. | Utilisation d'arn intronique pour mesurer l'expression genique |
US7668801B1 (en) * | 2003-04-21 | 2010-02-23 | At&T Corp. | Method and apparatus for optimizing queries under parametric aggregation constraints |
JP2007507222A (ja) * | 2003-05-28 | 2007-03-29 | ゲノミック ヘルス, インコーポレイテッド | 化学療法に対する応答を予測するための遺伝子発現マーカー |
AU2004248140A1 (en) * | 2003-05-30 | 2004-12-23 | Cedars-Sinai Medical Center | Gene expression markers for response to EGFR inhibitor drugs |
EP2327796A1 (fr) * | 2003-06-10 | 2011-06-01 | The Trustees Of Boston University | Méthodes de détection de troubles poulmonaires |
ES2690168T3 (es) | 2003-06-24 | 2018-11-19 | Genomic Health, Inc. | Predicción de la probabilidad de recidiva de cáncer |
WO2005008213A2 (fr) * | 2003-07-10 | 2005-01-27 | Genomic Health, Inc. | Algorithme de profile d'expression et test du pronostic du cancer |
US20100246837A1 (en) * | 2009-03-29 | 2010-09-30 | Krause Lee S | Systems and Methods for Tuning Automatic Speech Recognition Systems |
EP1678327A4 (fr) * | 2003-10-16 | 2007-10-10 | Genomic Health Inc | Systeme d'essai qrt-pcr pour le profilage d'expression genetique |
EP1681988B1 (fr) | 2003-11-12 | 2015-04-08 | The Children's Hospital Medical Center | Procede de diagnostic et de traitement de troubles pulmonaires |
US7552035B2 (en) * | 2003-11-12 | 2009-06-23 | Siemens Corporate Research, Inc. | Method to use a receiver operator characteristics curve for model comparison in machine condition monitoring |
US20070148650A1 (en) * | 2003-11-12 | 2007-06-28 | Trustees Of Boston University | Isolation of nucleic acid from mouth epithelial cells |
JP5192632B2 (ja) * | 2003-12-12 | 2013-05-08 | 愛知県 | 肺癌組織中の遺伝子発現強度を識別する方法 |
ES2360113T3 (es) | 2003-12-23 | 2011-06-01 | Genomic Health, Inc. | Amplificación universal de rna fragmentado. |
DE102004009934A1 (de) * | 2004-02-26 | 2005-09-22 | Niendorf, Axel, Prof.Dr.med. | Verfahren zur Untersuchung einer Gewebeprobe |
CA2848463A1 (fr) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Marqueurs d'expression genique permettant de predire la reponse a la chimiotherapie |
CA2571180A1 (fr) * | 2004-06-19 | 2006-01-05 | Chondrogene, Inc. | Systemes informatiques et procedes pour la construction de classifieurs biologiques et leurs utilisations |
US7991557B2 (en) * | 2004-06-19 | 2011-08-02 | Genenews Corporation | Computer system and methods for constructing biological classifiers and uses thereof |
CN101115848A (zh) * | 2004-11-03 | 2008-01-30 | 阿尔马科诊断有限公司 | 转录组微阵列技术及应用该技术的方法 |
WO2006052731A2 (fr) | 2004-11-05 | 2006-05-18 | Genomic Health, Inc. | Indicateurs moleculaires de pronostic de cancer du sein et prediction de reponse de traitement |
DK1836629T3 (da) * | 2004-11-05 | 2020-05-18 | Genomic Health Inc | Forudsigelse af respons på kemoterapi ved anvendelse af markører for genekspression |
US20060136417A1 (en) * | 2004-12-17 | 2006-06-22 | General Electric Company | Method and system for search, analysis and display of structured data |
US20060136259A1 (en) * | 2004-12-17 | 2006-06-22 | General Electric Company | Multi-dimensional analysis of medical data |
CN101313219B (zh) * | 2005-04-01 | 2016-10-05 | 麦德维特科学控股有限公司 | 一种诊断和治疗方法及其所使用的试剂 |
EP1874920A4 (fr) * | 2005-04-05 | 2009-11-04 | Cellpoint Diagnostics | Dispositifs et procédés permettant d'enrichir et de modifier des cellules tumorales circulantes et d'autres particules |
US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
EP2390347A1 (fr) | 2005-04-14 | 2011-11-30 | Trustees Of Boston University | Diagnostic des troubles pulmonaires à l'aide d'une prédiction de classe |
EP2325803A1 (fr) * | 2005-04-28 | 2011-05-25 | The General Hospital Corporation | Evaluation des informations de tomographie par cohérence optique pour une structure anatomique |
US7766231B2 (en) * | 2005-06-24 | 2010-08-03 | Schneider Electric USA, Inc. | Devices and methods for determining the amount of individual usage of a shared commodity |
US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
DK1934615T3 (da) | 2005-09-19 | 2014-07-14 | Janssen Diagnostics Llc | Fremgangsmåder og materialer til identificering af oprindelsen af et karcinom med ukendt primær oprindelse |
US20070078873A1 (en) * | 2005-09-30 | 2007-04-05 | Avinash Gopal B | Computer assisted domain specific entity mapping method and system |
US9347945B2 (en) | 2005-12-22 | 2016-05-24 | Abbott Molecular Inc. | Methods and marker combinations for screening for predisposition to lung cancer |
EP1806587A1 (fr) * | 2006-01-07 | 2007-07-11 | Université de Liège | Procédé in vitro de criblage de marqueurs biologiques accessibles dans des tissus pathologiques |
WO2007103541A2 (fr) | 2006-03-09 | 2007-09-13 | The Trustees Of Boston University | Méthodes de diagnostic et de pronostic pour troubles des poumons utilisant des profils d'expression de gènes de cellules épithéliales nasales |
US20100028914A1 (en) * | 2006-03-17 | 2010-02-04 | Mayo Foundation For Medical Education And Research | Assessing lung nodules |
EP2029779A4 (fr) | 2006-06-14 | 2010-01-20 | Living Microsystems Inc | Utilisation de génotypage snp fortement parallèle pour diagnostic fétal |
EP2589668A1 (fr) | 2006-06-14 | 2013-05-08 | Verinata Health, Inc | Analyse de cellules rares utilisant la division d'échantillons et les marqueurs d'ADN |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US7502767B1 (en) * | 2006-07-21 | 2009-03-10 | Hewlett-Packard Development Company, L.P. | Computing a count of cases in a class |
SI2084535T1 (sl) * | 2006-09-08 | 2016-08-31 | Richard Porwancher | Postopek diagnosticiranja s pomočjo bioinformatike |
US7599898B2 (en) * | 2006-10-17 | 2009-10-06 | International Business Machines Corporation | Method and apparatus for improved regression modeling |
JP5653042B2 (ja) * | 2007-01-16 | 2015-01-14 | ムスク ファウンデーション フォー リサーチ デベロップメント | 前立腺病変の診断、治療、及び予防用組成物及び方法 |
US7892770B2 (en) * | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
US8541183B2 (en) | 2007-09-11 | 2013-09-24 | Cancer Prevention And Cure, Ltd. | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof |
WO2010105235A2 (fr) * | 2009-03-12 | 2010-09-16 | Cancer Prevention And Cure, Ltd. | Procédés d'identification, d'évaluation, de prévention et de thérapie de maladies des poumons et leurs kits comprenant une identification, une évaluation, une prévention et une thérapie de maladies basées sur le sexe |
AU2008302076B2 (en) | 2007-09-19 | 2015-06-11 | The Trustees Of Boston University | Identification of novel pathways for drug development for lung disease |
US20090136945A1 (en) * | 2007-10-10 | 2009-05-28 | The Regents Of The University Of Michigan | Compositions and methods for assessing disorders |
WO2009121070A1 (fr) * | 2008-03-28 | 2009-10-01 | The Trustees Of Boston University | Procédés multifactoriels pour détecter des troubles pulmonaires |
WO2010021843A1 (fr) * | 2008-08-20 | 2010-02-25 | Eli Lilly And Company | Utilisation d’antifolates chez des patients présentant des taux détectables de tff-1 pour le traitement d’un cancer |
CN104198709A (zh) * | 2008-09-09 | 2014-12-10 | 私募蛋白质体公司 | 肺癌生物标记及其用途 |
US10359425B2 (en) | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
PL2562268T3 (pl) | 2008-09-20 | 2017-06-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nieinwazyjna diagnostyka aneuploidii płodu za pomocą sekwencjonowania |
US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
EP2356258A4 (fr) * | 2008-11-17 | 2012-12-26 | Veracyte Inc | Procédés et compositions de profilage moléculaire pour le diagnostic de maladies |
US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
US20100185568A1 (en) * | 2009-01-19 | 2010-07-22 | Kibboko, Inc. | Method and System for Document Classification |
US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
US8929630B2 (en) * | 2009-03-27 | 2015-01-06 | Life Technologies Corporation | Systems and methods for assessing images |
CN102459636B (zh) | 2009-05-07 | 2016-08-17 | 威拉赛特公司 | 用于诊断甲状腺病症的方法和组合物 |
US20130143747A1 (en) * | 2011-12-05 | 2013-06-06 | Myriad Genetics, Incorporated | Methods of detecting cancer |
US8811535B2 (en) * | 2009-07-17 | 2014-08-19 | Mitre Corporation | Time-frequency space constructions of families of signals |
WO2012033537A1 (fr) * | 2010-09-08 | 2012-03-15 | Nodality, Inc. | Références pour l'identification des cellules normales |
CA2717477A1 (fr) * | 2009-09-24 | 2011-03-24 | Heidi E. Wagner | Appareil et methode informatises et normalises pour guider les decisions portant sur des operations chirurgicales de pathologie anatomique |
US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
CA2789494C (fr) * | 2010-02-10 | 2021-08-17 | The Regents Of The University Of California | Biomarqueurs salivaires pour la detection du cancer du poumon |
AU2011289284B2 (en) | 2010-08-13 | 2015-04-09 | Somalogic Operating Co., Inc. | Pancreatic cancer biomarkers and uses thereof |
US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
WO2012070969A1 (fr) * | 2010-11-22 | 2012-05-31 | Farber Boris Slavinovich | Procédé diagnostique pour pronostiquer le développement et le contrôle de l'efficacité du traitement de maladies cardiovasculaires |
WO2012070970A1 (fr) * | 2010-11-22 | 2012-05-31 | Farber Boris Slavinovich | Procédé diagnostique pour pronostiquer le développement et le contrôle de l'efficacité du traitement de maladies cancéreuses |
US20140178901A1 (en) * | 2011-03-22 | 2014-06-26 | The General Hospital Corporation | Molecular Analysis of Tumor Samples |
WO2013045500A1 (fr) * | 2011-09-26 | 2013-04-04 | Universite Pierre Et Marie Curie (Paris 6) | Procédé de détermination d'une fonction prédictive pour discriminer des patients selon leur état d'activité de maladie |
JP6262218B2 (ja) * | 2012-06-14 | 2018-01-17 | エラスムス ユニバーシティ メディカルセンター ロッテルダムErasmus University Medical Center Rotterdam | 微小残存病変を検出するための方法、試薬およびキット。 |
US10158898B2 (en) | 2012-07-26 | 2018-12-18 | Comcast Cable Communications, Llc | Customized options for consumption of content |
EP3626308A1 (fr) | 2013-03-14 | 2020-03-25 | Veracyte, Inc. | Procédés d'évaluation de l'état d'une maladie pulmonaire obstructive chronique (copd) |
US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
GB201316524D0 (en) * | 2013-09-17 | 2013-10-30 | Medical Res Council | Biomarkers |
JP6685229B2 (ja) | 2014-02-17 | 2020-04-22 | シエナ キャンサー ダイアグノスティクス リミテッドSienna Cancer Diagnostics Ltd | 癌を検出する方法 |
EP3770274A1 (fr) | 2014-11-05 | 2021-01-27 | Veracyte, Inc. | Systèmes et procédés de diagnostic de la fibrose pulmonaire idiopathique sur des biopsies transbronchiques à l'aide de l'apprentissage automatique et de données de transcription dimensionnelle élevée |
US10101330B2 (en) | 2016-03-08 | 2018-10-16 | Magarray, Inc. | Protein and autoantibody biomarkers for the diagnosis and treatment of lung cancer |
WO2018009915A1 (fr) | 2016-07-08 | 2018-01-11 | Trustees Of Boston University | Biomarqueur basé sur l'expression génique pour la détection et la surveillance de lésions précancéreuses bronchiques |
US11360092B2 (en) * | 2016-08-05 | 2022-06-14 | The Research Foundation For The State University Of New York | Keratin 17 as a biomarker for bladder cancer |
EP3607089A4 (fr) | 2017-04-04 | 2020-12-30 | Lung Cancer Proteomics, LLC | Profilage de protéine à base de plasma pour le pronostic précoce du cancer du poumon |
US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
US20210042916A1 (en) * | 2018-02-07 | 2021-02-11 | Ai Technologies Inc. | Deep learning-based diagnosis and referral of diseases and disorders |
EP3935581A4 (fr) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | Compression et communication de données à l'aide d'un apprentissage automatique |
CN110970131B (zh) * | 2019-10-24 | 2024-01-26 | 中国医科大学附属盛京医院 | 一种基于免疫球蛋白定量检测的肾小球疾病分类分型模型及其应用 |
CN110807426B (zh) * | 2019-11-05 | 2023-11-21 | 苏州华文海智能科技有限公司 | 一种基于深度学习的寄生虫检测系统及方法 |
CN113049344B (zh) * | 2021-04-20 | 2022-02-01 | 深圳天烁生物科技有限公司 | 细胞染色的质控品制备方法 |
WO2023278468A1 (fr) * | 2021-06-29 | 2023-01-05 | The Regents Of The University Of Michigan | Méthodes de détermination du risque de récidive de cancer et le traitement associé |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4579827A (en) * | 1983-03-11 | 1986-04-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies |
WO1987006620A1 (fr) * | 1986-04-29 | 1987-11-05 | Murex Corporation | Kit de diagnostic pour maladies sexuellement transmissibles |
US4853770A (en) * | 1988-03-01 | 1989-08-01 | Joe Schneller | Video system for viewing microscopic specimens |
US5784162A (en) * | 1993-08-18 | 1998-07-21 | Applied Spectral Imaging Ltd. | Spectral bio-imaging methods for biological research, medical diagnostics and therapy |
US5543291A (en) | 1993-01-29 | 1996-08-06 | Dana Farber Cancer Institute | Method of detecting carcinoma |
CA2137786A1 (fr) | 1993-04-14 | 1994-10-27 | Murex Diagnostics Corporation | Dosage immunologique |
JPH08501455A (ja) * | 1993-05-24 | 1996-02-20 | アモコ・コーポレーション | Legionella属の細菌の検出のための核酸プローブおよび在郷軍人病の病因物質の検出方法 |
IT1270951B (it) | 1993-06-07 | 1997-05-26 | Boehringer Mannheim Italia | Metodo e dispositivo per il rilevamento simultano di neisseria gonorrhoeae, chlamydia trachomatis e mycoplasma |
EP0727664A3 (fr) | 1995-02-15 | 1996-11-20 | Bayer Ag | Marqueurs tumorales pour détecter la réapparition du cancer du sein |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
US5895748A (en) * | 1996-11-27 | 1999-04-20 | Johnson; Keith R. | Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies |
NO308755B1 (no) | 1996-12-20 | 2000-10-23 | Iystein Fodstad | FremgangsmÕte til karakterisering av unormale celler, anvendelse og sett for utførelse av fremgangsmÕten |
EP0961780B1 (fr) * | 1997-02-12 | 2007-04-11 | Electrophoretics Limited | Proteines-marqueurs pour le cancer du poumon et utilisation de ces dernieres |
PE20000121A1 (es) | 1997-10-21 | 2000-02-17 | Cancer Res Campaign Tech | Determinacion de anormalidad en el crecimiento celular |
AU3316600A (en) * | 1999-02-22 | 2000-09-21 | Torben F. Orntoft | Gene expression in bladder tumors |
AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
GB9926805D0 (en) * | 1999-11-13 | 2000-01-12 | Zeneca Ltd | Diagnostic methods |
GB0018140D0 (en) * | 2000-07-24 | 2000-09-13 | Medical Res Council | Screening for abnormalities |
US7219016B2 (en) * | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
-
2002
- 2002-03-12 CN CNA028097599A patent/CN1554025A/zh active Pending
- 2002-03-12 CA CA002440753A patent/CA2440753A1/fr not_active Abandoned
- 2002-03-12 US US10/095,298 patent/US20030199685A1/en not_active Abandoned
- 2002-03-12 EP EP02708460A patent/EP1373896A2/fr not_active Withdrawn
- 2002-03-12 WO PCT/GB2002/001125 patent/WO2002073204A2/fr active Application Filing
- 2002-03-12 KR KR10-2003-7011975A patent/KR20030094281A/ko not_active Application Discontinuation
- 2002-03-12 IL IL15787202A patent/IL157872A0/xx unknown
- 2002-03-12 NZ NZ528205A patent/NZ528205A/en unknown
- 2002-03-12 JP JP2002572414A patent/JP2004526154A/ja active Pending
- 2002-03-12 US US10/095,297 patent/US6939670B2/en not_active Expired - Fee Related
-
2003
- 2003-09-11 ZA ZA200307121A patent/ZA200307121B/en unknown
-
2005
- 2005-05-18 US US11/131,324 patent/US20050282201A1/en not_active Abandoned
-
2007
- 2007-09-25 US US11/902,789 patent/US20080139402A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20080139402A1 (en) | 2008-06-12 |
NZ528205A (en) | 2006-09-29 |
JP2004526154A (ja) | 2004-08-26 |
US20030199685A1 (en) | 2003-10-23 |
US20030104499A1 (en) | 2003-06-05 |
CN1554025A (zh) | 2004-12-08 |
EP1373896A2 (fr) | 2004-01-02 |
US6939670B2 (en) | 2005-09-06 |
WO2002073204A2 (fr) | 2002-09-19 |
CA2440753A1 (fr) | 2002-09-19 |
WO2002073204A3 (fr) | 2003-10-30 |
KR20030094281A (ko) | 2003-12-11 |
US20050282201A1 (en) | 2005-12-22 |
IL157872A0 (en) | 2004-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030104499A1 (en) | Cell-based detection and differentiation of lung cancer | |
ZA200502575B (en) | Cell-based detection and differentiation of disease states | |
Bravaccini et al. | PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis | |
Beasley et al. | Pleural mesothelioma classification update | |
Rohan et al. | Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk | |
Hasteh et al. | The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions | |
Morris et al. | Circulating biomarkers in hepatocellular carcinoma | |
Sari et al. | Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer | |
Ciancio et al. | Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer | |
Burford et al. | Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer | |
Loukeris et al. | Cytological cell blocks: predictors of squamous cell carcinoma and adenocarcinoma subtypes | |
Mhawech-Fauceglia et al. | IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma | |
Soh et al. | Immunoprofiling of colitis-associated and sporadic colorectal cancer and its clinical significance | |
Mawas et al. | MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung | |
Baniak et al. | Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes | |
Adkins et al. | SOX10 and GATA3 in adenoid cystic carcinoma and polymorphous adenocarcinoma | |
Babu et al. | Keratin 17 is a novel cytologic biomarker for urothelial carcinoma diagnosis | |
Ambrosini-Spaltro et al. | PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis | |
Kuperman et al. | Distinguishing benign from malignant mesothelial cells in effusions by Glut‐1, EMA, and Desmin expression: An evidence‐based approach | |
Brock et al. | A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results | |
Larson et al. | A limited immunohistochemical panel can subtype hepatocellular adenomas for routine practice | |
Chung et al. | Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal cancer tissue microarray | |
Yuda et al. | Biomarker discordance between primary breast cancer and bone or bone marrow metastases | |
AU2002242823A1 (en) | Cell-based detection and differentiation of disease states | |
Puglisi et al. | Balance between cell division and cell death as predictor of survival in patients with non-small-cell lung cancer |